Kura Investors

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015
DateTitle  
06/26/17Kura Oncology Added to Russell 3000® Index Printer Friendly Version
06/14/17Kura Oncology Presents Preliminary Clinical and Preclinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma Printer Friendly Version
06/07/17Kura Oncology Announces Data Presentations for Tipifarnib at the International Conference on Malignant Lymphoma and the European Hematology Association Annual Meeting Printer Friendly Version
05/30/17Kura Oncology to Participate in Two Upcoming Investor Conferences Printer Friendly Version
05/15/17Kura Oncology Reports First Quarter 2017 Operational and Financial Results Printer Friendly Version
05/08/17Kura Oncology to Report First Quarter 2017 Financial Results Printer Friendly Version
04/19/17Kura Oncology Granted U.S. Patent for Clinical-Stage ERK Inhibitor, KO-947 Printer Friendly Version
04/07/17Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947 Printer Friendly Version
04/05/17Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 and KO-539 Printer Friendly Version
03/29/17Preclinical Data for Kura Oncology Development Compounds to be Presented at AACR Annual Meeting 2017 Printer Friendly Version
03/14/17Kura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial Results Printer Friendly Version
03/07/17Kura Oncology to Report Fourth Quarter and Full Year 2016 Financial Results Printer Friendly Version
03/06/17Kura Oncology Reports Updated Clinical Activity Data in Ongoing Phase 2 Trial for Tipifarnib Printer Friendly Version
02/27/17Kura Oncology Announces Presentation of Preliminary Clinical Data for Tipifarnib in HRAS Mutant Squamous Cell Carcinomas of the Head and Neck at TAT 2017 Printer Friendly Version
02/09/17Kura Oncology to Participate in Three Upcoming Investor Conferences Printer Friendly Version
01/17/17Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia Printer Friendly Version
01/04/17Kura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 and Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor Program Printer Friendly Version
01/03/17Kura Oncology Appoints Steven Stein, M.D. to Board of Directors Printer Friendly Version